LAS VEGAS, NV–Cell MedX Corp. (OTCQB: CMXC) (“Cell MedX” or the “Company”) a development stage company focused on the discovery, development and commercialization of therapeutic devices for patients with diseases such as diabetes wishes to advise of recent events in both the diabetes sector and related corporate activities.
On September 8th, the Journal of the American Medical Association (JAMA) published a recent study titled “Prevalence of and Trends in Diabetes among Adults in the United States, 1988-2012” which states that in the United States, “49% to 52% of the population was estimated to have either diabetes or prediabetes.” With half the US population at risk, Cell MedX has committed to redoubling its efforts to commercialize its technology as rapidly as practicable.
To that end, the company has engaged with a European engineering and manufacturing firm to produce a prototype device within the next 30-60 days and continues to move ahead with clinical trials in Irvine, California. To-date a clinical setting staffed with appropriate personnel including a medical director, technicians and receptionist has been opened. Systems are in place, including equipment, training materials, medical records, forms and documentation. At this time the clinic is processing the first cohort of volunteers and additional volunteers are being sought. Interested diabetes patients in the Orange County area are invited to visit the recruitment web site at http://newportstudy.com and please sign up immediately. Acceptance is subject to certain criteria, but please consider contacting the team to see if you are a suitable candidate, as your involvement could be instrumental.
In related news, the Company is pleased to announce the appointment of Dr. Yousef Shihab to the Advisory Board. Dr. Shihab is a general surgeon with extensive experience in clinical research. During his career he has treated or attended a number of regional Heads of State in the Middle East. Dr. Shihab also served for 18 years (1976-1994) at the Al-Gamhouria Teaching Hospital, Aden, Yemen in a variety of positions and ultimately as Head of the Surgical Department. He was board certified in 1986 (Honors) at the University of Baghdad, Iraq, and earned a Bachelor’s Degree, Medicine & Surgery (Honors) at the University of Aden, Yemen. Since immigrating to North America, Dr. Shihab has been extensively involved in a number of medical device research studies.
With activities planned across a number of fronts in coming months, the Company has determined to engage the services of a professional spokesperson in order to better communicate its messaging to partners, stakeholders and investors as well as the public and diabetic population at large. Effective immediately, this role will be filled by Mr. Steven Bulwa, a leading technology expert and financial commentator with an eye for identifying early stage disruptive technologies. Mr. Bulwa is a prolific contributor on leading financial media such as The Street.com, The Huffington Post, Business Insider, and Seeking Alpha where he regularly contributed on health care technology. Mr. Bulwa intends to personally engage with the Company’s growing audience and looks forward to responding to questions submitted via the company website.
Cell MedX President and CEO Mr. Frank McEnulty notes, “The recent JAMA report really drives home the need for innovation in the diabetes sector. I welcome Yousef and Steven as they join the team at this exciting and increasingly busy juncture in the growth of the company.”
About Cell MedX Corp (OTCQB: CMXC)
Cell MedX Corp. is a development stage company focused on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes by developing technologies to help manage the illness and related complications. Through its wholly owned subsidiary, Avyonce Cosmedics Inc., Cell MedX Corp. is engaged in reselling and marketing of technology and equipment to the worldwide wellness industry as well as providing continuing education to health care professionals. For more information go to: www.cellmedx.com and visit us on Facebook.
On behalf of the Board of Directors of Cell MedX Corp.
Frank McEnulty
Chief Executive Officer and President.
Forward Looking Statements
This press release contains forward-looking statements. Forward-looking statements are subject to risks, uncertainties and assumptions and are identified by words such as “expects”, “aims”, “intends”, “estimates”, “projects”, “anticipates”, “believes”, “could”, “possibility” and other similar words. All statements addressing product performance, events, or developments that the Company expects or anticipates will occur in the future are forward-looking statements. Because the statements are forward-looking, they should be evaluated in light of important risk factors and uncertainties, some of which are described in the Company’s Quarterly, Annual and Current Reports filed with the United States Securities and Exchange Commission (the “SEC”). Should one or more of these risks or uncertainties materialize, or should any of the Company’s underlying assumptions prove incorrect, actual results may vary materially from those currently anticipated. In addition, undue reliance should not be placed on the Company’s forward-looking statements. In particular, the Company’s e-balance Technology is still in development. The Company does not currently have any commercially marketable products based on the e-balance technology, and there is no assurance that the Company will be successful in its development efforts. Except as required by law, Cell MedX Corp. disclaims any obligation to update or publicly announce any revisions to any of the forward-looking statements contained in this press release. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. No stock exchange, securities commission or other regulatory body has reviewed nor accepts responsibility for the adequacy or accuracy of this release. Investors are advised to carefully review the reports and documents that Cell MedX Corp. files from time to time with the SEC, including its Annual, Quarterly and Current Reports.
